Risk of progression differs in high risk and low risk cases when surgery is omitted Ductal carcinoma in situ (DCIS) is a non-obligate precursor lesion of invasive breast cancer. Since the ...

Researchers are hoping to find new ways to predict when an early form of breast cancer is likely to progress and develop new treatments for those at risk, thanks to new funding from Breast Cancer Now.

The FDA has authorized CLAIRITY BREAST, the first AI tool to predict a woman’s 5-year breast cancer risk using routine ...